Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual MeetingGlobeNewsWire • 04/12/24
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/16/24
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateGlobeNewsWire • 02/15/24
What Analyst Projections for Key Metrics Reveal About Ultragenyx (RARE) Q4 EarningsZacks Investment Research • 02/12/24
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate UpdateGlobeNewsWire • 02/08/24
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/08/24
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)GlobeNewsWire • 02/06/24
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman SyndromeGlobeNewsWire • 02/05/24
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseGlobeNewsWire • 01/25/24
After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is BrightZacks Investment Research • 01/10/24
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 MilestonesGlobeNewsWire • 01/07/24
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)GlobeNewsWire • 01/04/24
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman SyndromeGlobeNewsWire • 01/03/24
Does Ultragenyx (RARE) Have the Potential to Rally 87.43% as Wall Street Analysts Expect?Zacks Investment Research • 01/02/24
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)GlobeNewsWire • 12/18/23
Ultragenyx (RARE) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/02/23